Array BioPharma

Latest Headlines

Latest Headlines

Slumping Array aligns with Biogen on early autoimmune R&D

Array BioPharma has watched its shares fall steadily earthward since ex-partner Amgen backed out of a diabetes deal last summer, but a new deal with Big Biotech Biogen Idec sent the company up about 5% on renewed hopes for its early-stage R&D efforts.

Array slides as longtime CSO finds the exit

Array BioPharma Chief Scientific Officer Kevin Koch is leaving the biotech after 15 years, news that sent the company's shares down more than 5% on Thursday morning.

UPDATED: Cancer biotech upstart nabs $33M A round for R&D work, Array collaboration

Three months after in-licensing a preclinical cancer drug from Array BioPharma ($ARRY), the upstart biotech Loxo Oncology announced that it has a $33 million Series A lined up to fund the work ahead. 

Array slashes staff as Amgen pulls the plug on diabetes drug pact

Shares of Array BioPharma took a nasty dive Wednesday evening after Amgen pulled the plug on an ambitious four-year-old partnership to develop new Type 2 diabetes drugs. The company said it will have to ax 50 workers--20% of its staff--in response.

Celgene inks $11M inflammation deal with Array BioPharma

The arrangement with Array represents a relatively small upfront bet for Celgene, which has just forked over $100 million for an option to buy Acetylon and the Boston startup's HDAC6 inhibitor in early clinical development for myeloma.

Array BioPharma scores midstage success for asthma drug

Array BioPharma has another asset on deck for a potential partnership. The company has touted upbeat Phase II data for an experimental drug in patients with allergic asthma, and the company plans to seek a partner to fund further studies.

Array inks $434M licensing deal on cancer drug program

A New York-based biotech startup funded by Aisling Capital has stepped up to partner with Array BioPharma on a preclinical cancer program. Loxo Oncology will fund the preclinical work before taking over responsibility for the clinical trials.

AstraZeneca's selumetinib looks promising for rare cases of eye melanoma

As investigators narrow their search for effective remedies for more narrowly defined patient populations, clinical trials in oncology have sometimes begun to look more like the investigative work you find in the rare-disease arena. And nowhere was that more evident than in an ASCO presentation on the efficacy of AstraZeneca's selumetinib for rare cases of advanced melanoma in the eye.

Biotech exec settles up on an insider trading case

Back in the spring of 2010, James Lieberman landed a hot biotech stock tip. Unfortunately for him, though, it allegedly came from his boss and concerned his own company--Array BioPharma.

Array shares crater as pain drug disappoints in PhII

Array BioPharma  touted its latest mid-stage study of a key pain drug as an unqualified success, beating a placebo and hitting its primary endpoint when tested in patients suffering from osteoarthritis. But when investors dug down into the release and found that its experimental med did no better than a standard treatment, its shares slid more than 11%.